Therapeutic | Setoxaximab |
Target | Shiga Toxin Type 2 |
Heavy Chain | EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA |
Light Chain | DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Sunol Molecular Corporation, Uniformed Services University of the Health Sciences, BELLUS Health, Taro Pharmaceuticals Inc |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Haemolytic uraemic syndrome, Shiga-toxigenic Escherichia coli infections |
Notes |